CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops medicines targeting historically undruggable protein targets in cancer
Pitching HBM Healthcare? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room